Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged uremic animals

被引:49
作者
Fissell, WH [1 ]
Dyke, DB [1 ]
Weitzel, WF [1 ]
Buffington, DA [1 ]
Westover, AJ [1 ]
MacKay, SM [1 ]
Gutierrez, JM [1 ]
Humes, HD [1 ]
机构
[1] VA Med Ctr, Dept Med, Ann Arbor, MI USA
关键词
renal failure; cytokines; bioartificial kidney; sepsis; endotoxin shock;
D O I
10.1159/000046986
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The mortality from sepsis complicated by renal failure remains extremely high despite the application of modern renal replacement therapy. This study investigated whether treatment with a bioartificial kidney consisting of a hemofilter in a continuous venovenous hemofiltration circuit (CVVH) with a cartridge containing renal proximal tubule cells, also called the Renal Tubule Assist Device (RAD), would alter the course of sepsis in an animal model. The RAD has been previously characterized in vitro and ex vivo and provides transport, metabolic and endocrine activity. Mongrel dogs (n = 10) underwent surgical nephrectomy and 48 h later were treated with CVVH and either a RAD containing cells (n = 5) or an identically prepared sham cartridge (n = 5). After 4 h of therapy, intravenous endotoxin 2 mg/kg was infused over 1 h to simulate gram-negative septic shock. Data on blood pressure, cardiac output and systemic markers of inflammation were collected. Mean peak levels of an anti-inflammatory cytokine, IL-10, were significantly higher in cell-treated animals (15.25 vs. 6.29 ng/ml; p = 0.037), and mean arterial pressures were higher in cell-treated versus sham-treated animals (p < 0.04). We have demonstrated that treatment of an animal model of endotoxin shock and renal failure with a bioartificial kidney has measurable effects on circulating mediators of inflammation and on hemodynamic stability of the challenged animal. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:55 / 60
页数:6
相关论文
共 38 条
[11]   TUMOR NECROSIS FACTOR AND INTERLEUKIN-1 SERUM LEVELS DURING SEVERE SEPSIS IN HUMANS [J].
DAMAS, P ;
REUTER, A ;
GYSEN, P ;
DEMONTY, J ;
LAMY, M ;
FRANCHIMONT, P .
CRITICAL CARE MEDICINE, 1989, 17 (10) :975-978
[12]   Continuous renal replacement therapies in sepsis: where are the data? [J].
De Vriese, AS ;
Vanholder, RC ;
De Sutter, JH ;
Colardyn, FA ;
Lameire, NH .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (06) :1362-1364
[13]   THE PROINFLAMMATORY CYTOKINES INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR AND TREATMENT OF THE SEPTIC SHOCK SYNDROME [J].
DINARELLO, CA .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (06) :1177-1184
[14]   MEDIATORS, MECHANISMS AND MORTALITY IN MAJOR TRAUMA [J].
DONNELLY, SC ;
ROBERTSON, C .
RESUSCITATION, 1994, 28 (02) :87-92
[15]  
Fissell W. H., 2001, Journal of the American Society of Nephrology, V12, p264A
[16]   PRODUCTION OF INTERLEUKIN-6, TUMOR-NECROSIS-FACTOR-ALPHA AND INTERLEUKIN-10 IN-VITRO CORRELATES WITH THE CLINICAL IMMUNE DEFECT IN CHRONIC-HEMODIALYSIS PATIENTS [J].
GIRNDT, M ;
KOHLER, H ;
SCHIEDHELMWEICK, E ;
SCHLAAK, JF ;
ZUMBUSCHENFELDE, KHM ;
FLEISCHER, B .
KIDNEY INTERNATIONAL, 1995, 47 (02) :559-565
[17]   Impaired cellular immune function in patients with end-stage renal failure [J].
Girndt, M ;
Sester, U ;
Sester, M ;
Kaul, H ;
Köhler, H .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (12) :2807-2810
[18]   INTERLEUKIN-8 IN SEPSIS - RELATION TO SHOCK AND INFLAMMATORY MEDIATORS [J].
HACK, CE ;
HART, M ;
VANSCHIJNDEL, RJMS ;
EERENBERG, AJM ;
NUIJENS, JH ;
THIJS, LG ;
AARDEN, LA .
INFECTION AND IMMUNITY, 1992, 60 (07) :2835-2842
[19]   Evolving strategies in the treatment of sepsis and systemic inflammatory response syndrome (SIRS) [J].
Horn, KD .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1998, 91 (04) :265-277
[20]   Replacement of renal function in uremic animals with a tissue-engineered kidney [J].
Humes, HD ;
Buffington, DA ;
MacKay, SM ;
Funke, AJ ;
Weitzel, WF .
NATURE BIOTECHNOLOGY, 1999, 17 (05) :451-455